Journal
BLOOD
Volume 130, Issue 22, Pages 2373-2376Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2017-09-797712
Keywords
-
Categories
Ask authors/readers for more resources
On 1 September 2017, the US Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33(+) acute myeloid leukemia and for patients aged >= 2 years with CD33(+) acute myeloid leukemia who have experienced a relapse or who have not responded to initial treatment. This signals a new chapter in the long and unusual story of GO, which was the first antibody-drug conjugate approved for human use by the FDA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available